参考文献/References:
[1]Basile C, Davenport A, Mitra S, et al. Frontiers in hemodialysis: Innovations and technological advances. Artif Organs,2021,45(2):175-182.
[2]Eroglu E, Kocyigit I, Saraymen B, et al. The association of endothelial progenitor cell markers with arteriovenous fistula maturation in hemodialysis patients. Int Urol Nephrol,2016,48(6):891-899.
[3]Oh DJ, Lee JH, Kwon YE, et al. Relationship between arteriovenous fistula stenosis and circulating levels of neutrophil granule proteins in chronic hemodialysis patients. Ann Vasc Surg,2021,S0890-5096(21)00536-7.
[4]Luev J, Breznik S, Dinevski D, et al. Endovascular treatment of haemodialysis arteriovenous fistula with drugcoated balloon angioplasty: a singlecentre study. Cardiovasc Intervent Radiol,2018,41(6):882-889.
[5]Yildiz I. The efficacy of percutaneous transluminal angioplasty for the endovascular management of arteriovenous fistula dysfunction: a retrospective analysis in patients with endstage renal disease. Int Angiol,2020,39(4):341-348.
[6]Abdul Salim S, Tran H, Thongprayoon C, et al. Comparison of drugcoated balloon angioplasty versus conventional angioplasty for arteriovenous fistula stenosis: Systematic review and metaanalysis. J Vasc Access,2020,21(3):357-365.
[7]Ansotegui IJ, Melioli G, Canonica GW, et al. IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. World Allergy Organ J,2020,13(2):100080.
[8]Yazar O, Provoost A, Broughton A, et al. Paclitaxel drugcoated balloon angioplasty for the treatment of failing arteriovenous fistulas: a singlecenter experience. Acta Chir Belg,2020,120(2):85-91.
[9]Katsanos K, Karnabatidis D, Kitrou P, et al. Paclitaxelcoated balloon angioplasty vs. plain balloon dilation for the treatment of failing dialysis access: 6month interim results from a prospective randomized controlled trial. J Endovasc Ther,2012,19(2):263-272.
[10]Hawkins BM, Meier IC. Drugcoated balloon, limb ischemia, and the elephant in the room. JACC Cardiovasc Interv,2020,13(19):2300-2302.
[11]Chang GH, Azar DA, Lyle C, et al. Intrinsic coating morphology modulates acute drug transfer in drugcoated balloon therapy. Sci Rep,2019,9(1):6839.
[12]Picard M. Management of hypersensitivity reactions to taxanes. Immunol Allergy Clin North Am,2017,37(4):679-693.
[13]Yamamoto T, Natio M, Hara S, et al. The effect of aprepitant and dexamethasone combination on paclitaxelinduced hypersensitivity reaction. Eur J Gynaecol Oncol,2016,37(6):833-836.
[14]Narroway HG, Katib N, Gomes ML, et al. Kounis syndrome after angioplasty of the superficial femoral artery with paclitaxelcoated balloon. Ann Vasc Surg,2020,69:450.e17-450.e22.
[15]Lake E,Twigg M, Farquharson F. Acute hypersensitivity reaction to femoral drugcoated balloons. Vasa,2017,46(3):223-225.
[16]Thomas SD, McDonald RR, Varcoe RL. Vasculitis resulting from a superficial femoral artery angioplasty with a paclitaxeleluting balloon. J Vasc Surg,2014,59(2):520-523.